Erythromycin Topical Gel USP — Class II drug recall D-0716-2022
Terminated recall by Teligent Pharma, Inc., reported 2022-02-23, distributed nationwide. Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.
| Recall number | D-0716-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teligent Pharma, Inc., Buena, NJ, United States |
| Recall initiated | 2022-02-07 |
| Classified | 2022-03-24 |
| Reported by FDA | 2022-02-23 |
| Terminated | 2024-05-09 |
| Distributed | Nationwide (US) |
| Quantity | 11,040 tubes |
| Reason classes | specification failure |
| NDC | 63739-0053-66 |
| Lot numbers | 15724 |
| Expiration dates | 2022-06 |
Product
Erythromycin Topical Gel USP, 2%, Net Wt 30 g tube, Rx only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, Distributed by: McKesson Corporation, dba Sky Packaging, 4971 Southridge Blvd., Suite 101, Memphis, TN 38141, NDC 63739-053-66.
Reason for recall
Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0716-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.